Oral Lung-Selective Bispecifics

About Theravance Biopharma

Theravance Biopharma is dedicated to transforming the treatment of specialty respiratory diseases through the discovery and development of 'Medicines that Make a Difference®'. The company achieved a significant milestone with the FDA approval and commercialization of YUPELRI® for COPD, which is co-commercialized with Viatris in the United States. With a strategic focus on insight, innovation, and managing uncertainty, Theravance Biopharma aims to create shareholder value by advancing its pipeline of organ-selective medicines for serious lung diseases. Its leadership team brings decades of experience from major pharmaceutical companies, guiding the company's integrated research, development, and commercial efforts.

Therapeutic Areas

Other Serious Respiratory Diseases Drugs